Somatostatin Analogs Market Report 2024: Global Trends, Forecast and Competitive Analysis to 2030 - Opportunities in the Acromegaly and Neuroendocrine Tumor Markets
February 16, 2024 05:18 ET
|
Research and Markets
Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Global Somatostatin Analogs Market to Reach $8.67 Billion by 2028 - Forecast Shows Rapid Growth in Asia-Pacific and Innovation Trends
January 25, 2024 05:42 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global market for somatostatin...
Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
October 16, 2023 05:30 ET
|
Research Nester
New York, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is slated to expand at ~6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10...
Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
October 03, 2023 07:00 ET
|
Research Nester
New York, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is predicted to expand at ~ 6% CAGR between 2023 and 2035. The market is projected to garner a revenue of USD...
Global Somatostatin Analogs Market Intelligence Report to 2027 - Featuring CVS Health, Ipsen Pharma and Pfizer Among Others
July 25, 2022 06:43 ET
|
Research and Markets
Dublin, July 25, 2022 (GLOBE NEWSWIRE) -- The "Somatostatin Analogs Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global...
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 16:11 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
March 19, 2019 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...